Slingshot members are tracking this event:
Gilead (GILD) Plans to Submit FDA Application for Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients by End of 2016
Slingshot Insights Explained
Dec 08, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fda, Regulatory Application, Sofosbuvir, Velpatasvir, Voxilaprevir, Triple Combo Pill, Treatment-experienced, Genotype 1-6, Chronic Hcv